Fig. 3: Evaluation of prognosis and druggability of CTCFL-regulated genes in ovarian cancer tumor samples.
From: CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy
a Relative expression of the 34 CTCFL-regulated candidate genes in normal and tumor samples (left panel) and their corresponding fold change (right panel). Genes are grouped into DEGs (p-adj < 0.05) or not DEGs (p-adj ≥ 0.05). b Survival analysis with Cox PH model using four survival data: overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFI). c Average Concordance Index (CI) obtained with the gene expression of the 34 candidate genes using the random survival forest (RSF) model. The dashed horizontal line indicates the average CI of random sets of genes for each survival dataset. d Kaplan–Meier plots of MALT1 (top relevant gene found by OS and DSS RSF models) in combination with CTCFL expression. e CTCFL-regulated protein interaction network found in vitro depicting the druggable targets that are differentially expressed in tumor samples versus normal tissue (TCGA vs GTEx). Red and blue nodes indicate genes upregulated and downregulated in tumor vs normal, respectively. Targeting drugs are shown in red boxes, red drug labels indicate drugs currently clinically used for OC treatment.
